Abstract:Copyright: © 2013 Qiu L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited In the latest several decades, we have witnessed the striking development of synthetic polymers as drug carriers from the early issue as implant agents to update various nano-scaled drug delivery systems via transmucosal, oral or intravenous administration. Of these, polymeric nanoparticles delivering anti-cancer drugs, biomacromolecular antibody or genetic substance such as DNA or siRNA to tumor have received predominant attention. In these delivery systems, the polymers play important roles to improve the solubility, regulate the biodistribution, prolong the half-life and control the release of drug, consequently enhanced therapy efficacy and minimized side effect has been expected. By now, quite many polymers have been explored and it has been found that different pharmaceutical formulations would lead to different results. Therefore, the rational design of polymer and formulation, and then the proper combination of both of them is the prerequisite to fabricate a successful drug delivery system. The major method to design optimal polymer can be classified to top-down and bottom-up methods [1]. Bottomup design methods prepare the polymer derivations on the basis of chemical properties of polymers, while top-down design method is adopted to modify the polymer considering the requirement of cancer therapy. Using bottom-up method, it is easier for chemists to acquire a large quantity of novel polymers, but most of them finally fail to meet the demand of clinical application. On the contrary, top-down method directly aims to clinical application of polymers and the corresponding formulation. With this idea, how to synthesize objective polymer is always the difficulty for those researches working in clinic. Obviously, merging these two methods together is an ideal method to facilitate the development of functional polymers and their transfer from the lab to practical application. Herein, I focus on amphiphilic polymer design for cancer therapy.

Polyphophazenes As Anti-Cancer Drug Carriers: from Synthesis to Application

Synthesis of Amino‐cosubstituted Polyorganophosphazenes and Fabrication of Their Nanoparticles for Anticancer Drug Delivery

Self-assembled polymer nanostructures for delivery of anticancer therapeutics

Recent Research Progress on Polyphosphazene-Based Drug Delivery Systems

Synthesis of Polyorganophosphazenes and Fabrication of Their Blend Microspheres and Micro/nanofibers As Drug Delivery Systems

Supramolecular polymeric prodrug micelles for efficient anticancer drug delivery

Polymeric Drug Delivery System Based on Pluronics for Cancer Treatment

Polymeric Prodrug by Supramolecular Polymerization

Therapeutic poly(amino acid)s as drug carriers for cancer therapy

Fluorinated Organic Polymers for Cancer Drug Delivery

Polysaccharide-Drug Conjugates: A Tool for Enhanced Cancer Therapy

Poly(phenylalanine) and poly(3,4-dihydroxy-L-phenylalanine): Promising biomedical materials for building stimuli-responsive nanocarriers

Polymer-Based Drug Delivery Systems for Cancer Therapeutics

Polyhydroxyalkanoates (PHAs) and its copolymer nanocarrier application in cancer treatment: An overview and challenges

Synthesis of Reductive Responsive Polyphosphazenes and Their Fabrication of Nanocarriers for Drug Delivery Application

Polymer-Drug Conjugates: Novel Carriers for Cancer Chemotherapy

Synthesis of Polyorganophosphazenes and Preparation of Their Polymersomes for Reductive/acidic Dual-Responsive Anticancer Drugs Release

Polymeric nanoparticles-Promising carriers for cancer therapy

Cyclodextrin-Based Polymeric Drug Delivery Systems for Cancer Therapy

Rational Design of Synthetic Polymers As Drug Carriers for Cancer Therapy

Construction of Amphiphilic Copolymer Nanoparticles Based on Hyperbranched Poly (Amine-Ester) and 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine As Drug Carriers for Cancer Therapy.